Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 4/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.39 |
| ▸ | PYGM | P11217 | 1/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.39 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.39 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16340896 | 0.91 | TK2 (0.42) | TYMPTK2LGALS3PYGMLGALS9 | |
| SCHEMBL9135382 | 0.88 | LGALS9 (0.38) | TK2LGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL18561507 | 0.85 | KMT2A (0.34) | ALDH1A1 | |
| SCHEMBL14929106 | 0.85 | KMT2A (0.34) | ALDH1A1 | |
| SCHEMBL16341608 | 0.84 | LGALS8 (0.37) | TK2LGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL23906013 | 0.77 | TSHR (0.47) | ALDH1A1 | |
| SCHEMBL16781791 | 0.77 | TSHR (0.47) | ALDH1A1 | |
| SCHEMBL16807741 | 0.77 | TSHR (0.47) | ALDH1A1 | |
| SCHEMBL14928934 | 0.77 | KMT2A (0.33) | ALDH1A1 | |
| SCHEMBL16805352 | 0.77 | KMT2A (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | TYMP 32/4885TK2 151/4885LGALS3 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.